0001415889-22-000715.txt : 20220121 0001415889-22-000715.hdr.sgml : 20220121 20220121204118 ACCESSION NUMBER: 0001415889-22-000715 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220121 FILED AS OF DATE: 20220121 DATE AS OF CHANGE: 20220121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Guarino Jonathan L. CENTRAL INDEX KEY: 0001787282 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14778 FILM NUMBER: 22547250 MAIL ADDRESS: STREET 1: 100 WELLESLEY WAY CITY: FREEHOLD STATE: NJ ZIP: 07728 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SOLIGENIX, INC. CENTRAL INDEX KEY: 0000812796 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 411505029 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE B-10 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-538-8200 MAIL ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE B-10 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: DOR BIOPHARMA INC DATE OF NAME CHANGE: 20020329 FORMER COMPANY: FORMER CONFORMED NAME: ENDOREX CORP DATE OF NAME CHANGE: 19960916 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19920703 4 1 form4-01212022_050109.xml X0306 4 2022-01-21 0000812796 SOLIGENIX, INC. SNGX 0001787282 Guarino Jonathan L. C/O SOLIGENIX, INC. 29 EMMONS DRIVE, SUITE B-10 PRINCETON NJ 08540 false true false false CHIEF FINANCIAL OFFICER Option (Right to Buy) 0.78 2022-01-21 4 A 0 50000 0 A 2021-12-09 2031-12-08 Common Stock 50000 50000 D The terms of the stock option provide that it is to vest immediately as to 12,500 shares and to vest as to the remainder at a rate of 3,125 of the shares every three months, beginning on March 12, 2022; provided, however, that, consistent with the 2015 Equity Incentive Plan (the "Plan") and the rules of the Nasdaq Stock Market, such stock option shall not be exercisable nor shall it vest prior to the time when an amendment increasing the number of shares authorized for issuance under the Plan is approved by the stockholders, and provided further that, if such approval has not been obtained within 12 months of the grant date, the stock option shall thereupon be canceled and become null and void. The reporting person voluntarily agreed to cancel the stock option granted December 9, 2021 with respect to 50,000 shares. /s/ Jonathan L. Guarino 2022-01-21